Thursday, June 6, 2013
NeuroVive Pharmaceutical AB, of Stockholm, Sweden, recruited the first patient in a Phase IIa trial evaluating safety and pharmacokinetics of the company's NeuroSTAT drug candidate in traumatic brain injury. The open-label, uncontrolled study, which is being conducted at Copenhagen (Denmark) University Hospital, expects to enroll 20 patients.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.